# EDGAR Filing Document

**Accession Number:** 0001178711
**File Stem:** 0001628280-23-008462
**Filing Date:** 2023-3
**Character Count:** 26876
**Document Hash:** aa30c020c64e8a83038dbd0e1d89a6db
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-008462.hdr.sgml**: 20230317

**ACCESSION NUMBER**: 0001628280-23-008462

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230317

**DATE AS OF CHANGE**: 20230317

**EFFECTIVENESS DATE**: 20230317

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Paratek Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001178711
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 330960223
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270646
- **FILM NUMBER:** 23742379

**BUSINESS ADDRESS:**
- **STREET 1:** 75 PARK PLAZA
- **STREET 2:** 4TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** (617) 807-6600

**MAIL ADDRESS:**
- **STREET 1:** 75 PARK PLAZA
- **STREET 2:** 4TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Transcept Pharmaceuticals Inc
- **DATE OF NAME CHANGE:** 20090130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVACEA INC
- **DATE OF NAME CHANGE:** 20020724

**Registration No. 333-**

**As filed with the Securities and Exchange Commission on March 17, 2023**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE**

**SECURITIES ACT OF 1933**

**PARATEK PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **33-0960223** |
| (State or other jurisdiction of<br>incorporation or organization) | (IRS Employer<br>Identification No.) |

---

---

| |
|:---|
| **75 Park Plaza**<br>**Boston, MA 02116** |
| (Address of Principal Executive Offices) (Zip Code) |

---

**Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan**

(Full titles of the plans)

**Evan Loh, M.D.<br>Chief Executive Officer<br>75 Park Plaza**

**Boston, MA 02116**

(Name and address of agent for service)

**(617) 807-6600**

(Telephone number, including area code, of agent for service)

**Please send copies of all communications to:**

---

| | |
|:---|:---|
| **William M. Haskel**<br>**Chief Legal Officer, General Counsel and Corporate Secretary**<br>**Paratek Pharmaceuticals, Inc.**<br>**75 Park Plaza**<br>**Boston, MA 02116**<br>**(617) 807-6600** | **Thomas J. Danielski**<br>**Christopher D. Comeau**<br>**Ropes & Gray LLP**<br>**Prudential Tower**<br>**800 Boylston Street**<br>**Boston, MA 02199**<br>**(617) 951-7000** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ☐ | Accelerated filer ☒ |
| Non-accelerated filer ☐ | Smaller reporting company ☒ |
|  | Emerging growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

&nbsp;&nbsp;&nbsp;&nbsp;

132189852_6

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed to register an additional 2,832,577 shares under the Registrant's 2015 Equity Incentive Plan. Pursuant to Instruction E to Form S-8, the Registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of its Registration Statement on Form S-8 (<u>[File No. 333-205482](https://www.sec.gov/Archives/edgar/data/1178711/000119312515244442/d62048ds8.htm)</u>) filed with the Securities and Exchange Commission (the "SEC") on July 2, 2015, its Registration Statement on Form S-8 (<u>[File No. 333-210053](https://www.sec.gov/Archives/edgar/data/1178711/000156459016014315/prtk-s8_20160309.htm)</u>) filed with the SEC on March 9, 2016, its Registration Statement on Form S-8 (<u>[File No. 333-217660](https://www.sec.gov/Archives/edgar/data/1178711/000119312517158553/d355224ds8.htm)</u>) filed with the SEC on May 4, 2017, its Registration Statement on Form S-8 (<u>[File No. 333-224781](https://www.sec.gov/Archives/edgar/data/1178711/000156459018012380/prtk-s8.htm)</u>) filed with the SEC on May 9, 2018, its Registration Statement on Form S-8 (<u>[File No. 333-230097](https://www.sec.gov/Archives/edgar/data/1178711/000156459019006490/prtk-s8.htm)</u>) filed with the SEC on March 6, 2019, its Registration Statement on Form S-8 (<u>[File No. 333-237084](https://www.sec.gov/Archives/edgar/data/1178711/000156459020010054/prtk-s8.htm)</u>) filed with the SEC on March 11, 2020, its Registration Statement on Form S-8 (<u>[File No. 333-254857](https://www.sec.gov/Archives/edgar/data/1178711/000156459021016644/prtk-s8.htm)</u>), filed with the SEC on March 30, 2021, and its Registration Statement on Form S-8 (<u>[File No. 333-263579](https://www.sec.gov/Archives/edgar/data/1178711/000156459022010430/prtk-s8.htm)</u>), filed with the SEC on March 15, 2022.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 8. Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
|<br>**Exhibit<br>Number** | **Description** | **Schedule / Form** | **<u>File Number</u>** | **<u>Exhibit</u>** | **<u>Filing Date</u>** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation of Paratek Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1178711/000119312514391396/d811418dex31.htm)</u> | Form 8-K | 001-36066 | 3.1 | October 31, 2014 |
| 4.2 | <u>[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Paratek Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1178711/000119312514391396/d811418dex32.htm)</u> | Form 8-K | 001-36066 | 3.2 | October 31, 2014 |
| 4.3 | <u>[Certificate of Elimination of Series A Junior Participating Preferred Stock.](https://www.sec.gov/Archives/edgar/data/1178711/000119312515262754/d152427dex31.htm)</u> | Form 8-K | 001-36066 | 3.1 | July 24, 2015 |
| 4.4 | <u>[Amended and Restated Bylaws.](https://www.sec.gov/Archives/edgar/data/1178711/000119312515133353/d912706dex31.htm)</u> | Form 8-K | 001-36066 | 3.1 | April 16, 2015 |
| 4.5 | <u>[Specimen Common Stock Certificate.](https://www.sec.gov/Archives/edgar/data/1178711/000119312515008217/d847276dex42.htm)</u> | Form S-3 | 333-201458 | 4.2 | January 12, 2015 |
| 4.6 | <u>[2015 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1178711/000119312515244442/d62048dex995.htm)</u> | Form S-8 | 333-205482 | 99.5 | July 2, 2015 |
| 4.7 | <u>[Form of Stock Option Grant Notice and Option Agreement under the 2015 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1178711/000119312515244442/d62048dex996.htm)</u> | Form S-8 | 333-205482 | 99.6 | July 2, 2015 |
| 4.8 | <u>[Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1178711/000119312515244442/d62048dex997.htm)</u> | Form S-8 | 333-205482 | 99.7 | July 2, 2015 |
| 4.9 | <u>[Form of Leadership Team Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1178711/000156459017015699/prtk-ex101_19.htm)</u> | Form 8-K | 001-36066 | 10.1 | August 4, 2017 |
| 4.10 | <u>[Form of Director Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2015 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1178711/000156459018004551/prtk-ex106e_1535.htm)</u> | Form 10-K | 001-36066 | 10.6E | March 6, 2018 |
| 4.11 | <u>[Form of Director Stock Option Grant Notice and Option Agreement under the 2015 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1178711/000156459018004551/prtk-ex106f_1534.htm)</u> | Form 10-K | 001-36066 | 10.6F | March 6, 2018 |
| 5.1\* | <u>[Opinion of Ropes & Gray LLP](parateks-8ex51opinion2023e.htm)</u> |  |  |  |  |
| 23.1\* | <u>[Consent of Ernst & Young LLP, an independent registered public accounting firm](a231-2022eyconsentforsx8fi.htm)</u> |  |  |  |  |
| 23.3\* | <u>[Consent of Ropes & Gray LLP (contained in Exhibit 5.1 to this Registration Statement)](parateks-8ex51opinion2023e.htm)</u> |  |  |  |  |
| 24.1 | <u>[Power of Attorney (included on the signature page of this Registration Statement)](#ia81579ccb36f42229ee18618352a0df8_4752)</u> |  |  |  |  |
| 107\* | <u>[Filing Fee Table](ex-107xparatekxformsx8fili.htm)</u> |  |  |  |  |

---

________________

 \* Filed herewith.

****

<br> &nbsp;&nbsp;&nbsp;&nbsp;

132189852_6

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 17th day of March, 2023.

---

| | |
|:---|:---|
| **PARATEK PHARMACEUTICALS, INC.** | **PARATEK PHARMACEUTICALS, INC.** |
| By: | /s/ Evan Loh |
|  | Name: Evan Loh, M.D. |
|  | Title: Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Sarah Higgins and William M. Haskel, and each of them acting individually, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Paratek Pharmaceuticals, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

\* \* \* \*

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Evan Loh | Chief Executive Officer and Director | March 17, 2023 |
| Evan Loh, M.D. | *(Principal Executive Officer)* |  |
| /s/ Sarah Higgins | Vice President, Finance and Controller | March 17, 2023 |
| Sarah Higgins | *(Principal Financial and Accounting Officer)* |  |
| /s/ Michael F. Bigham | Executive Chairman and Director | March 17, 2023 |
| Michael F. Bigham |  |  |
| /s/ Minnie Baylor-Henry | Director | March 17, 2023 |
| Minnie Baylor-Henry |  |  |
| /s/ Thomas J. Dietz | Director | March 17, 2023 |
| Thomas J. Dietz, Ph. D. |  |  |
| /s/ Timothy R. Franson | Director | March 17, 2023 |
| Timothy R. Franson, M.D. |  |  |
| /s/ Rolf K. Hoffmann | Director | March 17, 2023 |
| Rolf K. Hoffmann |  |  |
| /s/ Kristine Peterson | Director | March 17, 2023 |
| Kristine Peterson |  |  |
| /s/ Robert S. Radie | Director | March 17, 2023 |
| Robert S. Radie |  |  |
| /s/ Jeffrey Stein | Director | March 17, 2023 |
| Jeffrey Stein, Ph.D. |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;

132189852_6

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Paratek Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Share**<sup>(3)</sup> | **Maximum Aggregate Offering Price**<sup>(3)</sup> | **Fee Rate** | **Amount of Registration Fee**<sup>(3)</sup> |
| Equity | Equity | Common Stock, $0.001 par value per share | 457(c) and 457(h) | 2832577<sup>(2)</sup> | $1.50 | $4248865.50 | 0.0001102 | $468.23 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Offering Amounts** |  | $4248865.50 |  | $468.23 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Fee Offsets** |  |  |  | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net Fee Due** |  |  |  | $468.23 |
| (1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions. | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions. | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions. | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions. | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions. | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions. | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions. | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions. |
| (2) | Represents 2,832,577 shares of Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2015 Equity Incentive Plan (the "2015 Plan") on January 1, 2023 pursuant to an "evergreen" provision contained in the 2015 Plan. The "evergreen" provision provides that on each January 1st from January 1, 2015 through January 1, 2025, the number of shares of Common Stock available for issuance under the 2015 Plan will automatically increase annually in an amount equal to the lesser of 5% of outstanding shares of the Registrant's Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the Registrant's board of directors. | Represents 2,832,577 shares of Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2015 Equity Incentive Plan (the "2015 Plan") on January 1, 2023 pursuant to an "evergreen" provision contained in the 2015 Plan. The "evergreen" provision provides that on each January 1st from January 1, 2015 through January 1, 2025, the number of shares of Common Stock available for issuance under the 2015 Plan will automatically increase annually in an amount equal to the lesser of 5% of outstanding shares of the Registrant's Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the Registrant's board of directors. | Represents 2,832,577 shares of Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2015 Equity Incentive Plan (the "2015 Plan") on January 1, 2023 pursuant to an "evergreen" provision contained in the 2015 Plan. The "evergreen" provision provides that on each January 1st from January 1, 2015 through January 1, 2025, the number of shares of Common Stock available for issuance under the 2015 Plan will automatically increase annually in an amount equal to the lesser of 5% of outstanding shares of the Registrant's Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the Registrant's board of directors. | Represents 2,832,577 shares of Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2015 Equity Incentive Plan (the "2015 Plan") on January 1, 2023 pursuant to an "evergreen" provision contained in the 2015 Plan. The "evergreen" provision provides that on each January 1st from January 1, 2015 through January 1, 2025, the number of shares of Common Stock available for issuance under the 2015 Plan will automatically increase annually in an amount equal to the lesser of 5% of outstanding shares of the Registrant's Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the Registrant's board of directors. | Represents 2,832,577 shares of Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2015 Equity Incentive Plan (the "2015 Plan") on January 1, 2023 pursuant to an "evergreen" provision contained in the 2015 Plan. The "evergreen" provision provides that on each January 1st from January 1, 2015 through January 1, 2025, the number of shares of Common Stock available for issuance under the 2015 Plan will automatically increase annually in an amount equal to the lesser of 5% of outstanding shares of the Registrant's Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the Registrant's board of directors. | Represents 2,832,577 shares of Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2015 Equity Incentive Plan (the "2015 Plan") on January 1, 2023 pursuant to an "evergreen" provision contained in the 2015 Plan. The "evergreen" provision provides that on each January 1st from January 1, 2015 through January 1, 2025, the number of shares of Common Stock available for issuance under the 2015 Plan will automatically increase annually in an amount equal to the lesser of 5% of outstanding shares of the Registrant's Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the Registrant's board of directors. | Represents 2,832,577 shares of Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2015 Equity Incentive Plan (the "2015 Plan") on January 1, 2023 pursuant to an "evergreen" provision contained in the 2015 Plan. The "evergreen" provision provides that on each January 1st from January 1, 2015 through January 1, 2025, the number of shares of Common Stock available for issuance under the 2015 Plan will automatically increase annually in an amount equal to the lesser of 5% of outstanding shares of the Registrant's Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the Registrant's board of directors. | Represents 2,832,577 shares of Common Stock that were automatically added to the shares authorized for issuance under the Registrant's 2015 Equity Incentive Plan (the "2015 Plan") on January 1, 2023 pursuant to an "evergreen" provision contained in the 2015 Plan. The "evergreen" provision provides that on each January 1st from January 1, 2015 through January 1, 2025, the number of shares of Common Stock available for issuance under the 2015 Plan will automatically increase annually in an amount equal to the lesser of 5% of outstanding shares of the Registrant's Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the Registrant's board of directors. |
| (3) | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Registrant's common stock on the Nasdaq Global Market on March 16, 2023. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Registrant's common stock on the Nasdaq Global Market on March 16, 2023. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Registrant's common stock on the Nasdaq Global Market on March 16, 2023. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Registrant's common stock on the Nasdaq Global Market on March 16, 2023. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Registrant's common stock on the Nasdaq Global Market on March 16, 2023. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Registrant's common stock on the Nasdaq Global Market on March 16, 2023. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Registrant's common stock on the Nasdaq Global Market on March 16, 2023. | Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the Registrant's common stock on the Nasdaq Global Market on March 16, 2023. |

---

132189145_3

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![ropesgray.jpg](ropesgray.jpg) | ROPES & GRAY LLP<br>PRUDENTIAL TOWER<br>800 BOYLSTON STREET<br>BOSTON, MA 02199-3600<br>WWW.ROPESGRAY.COM |

---

March 17, 2023

Paratek Pharmaceuticals, Inc.<br>75 Park Plaza

Boston, MA 02116

Re:&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

This opinion is furnished to you in connection with the registration statement on Form S-8 (the "<u>Registration Statement</u>"), filed with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), for the registration of an aggregate of 2,832,577 shares of common stock, $0.001 par value (the "<u>Shares</u>"), of Paratek Pharmaceuticals, Inc., a Delaware corporation (the "<u>Company</u>"), issuable under the Company's 2015 Equity Incentive Plan (the "<u>Plan</u>").

We are familiar with the actions taken by the Company in connection with the adoption of the Plan. For purposes of our opinion, we have examined and relied upon such documents, records, certificates and other instruments as we have deemed necessary.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the Plan, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

Very truly yours,

/s/ Ropes & Gray LLP

Ropes & Gray LLP

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan of our reports dated March 16, 2023, with respect to the consolidated financial statements of Paratek Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Paratek Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 17, 2023

<br>